Last update 08 May 2025

MHU-650

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms-
Target-
Action-
Mechanism-
Therapeutic Areas
Cardiovascular DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]
Active Indication-
Inactive Indication
Diabetic macular oedemaMacular EdemaRetinal Vein Occlusion+ [1]
Originator Organization
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
Active Organization-
Inactive Organization
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with MHU-650
NCT04635800
/ CompletedPhase 1
A First-in-human, Open-label, Single Ascending Dose Study to Assess Safety and Tolerability of Intravitreal MHU650 in Participants With Macular Edema From Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (nAMD), or Retinal Vein Occlusion (RVO)
100 Clinical Results associated with MHU-650
Login to view more data
100 Translational Medicine associated with MHU-650
Login to view more data
100 Patents (Medical) associated with MHU-650
Login to view more data
100 Deals associated with MHU-650
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetic macular oedemaPhase 1
Puerto Rico
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
10 Dec 2020
Diabetic macular oedemaPhase 1
United States
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
10 Dec 2020
Macular EdemaPhase 1
Puerto Rico
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
10 Dec 2020
Macular EdemaPhase 1
United States
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
10 Dec 2020
Retinal Vein OcclusionPhase 1
United States
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
10 Dec 2020
Retinal Vein OcclusionPhase 1
Puerto Rico
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
10 Dec 2020
Wet age-related macular degenerationPhase 1
Puerto Rico
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
10 Dec 2020
Wet age-related macular degenerationPhase 1
United States
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.
10 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free